Abstract:OBJECTIVE Cardiotoxicity refers to drug-induced arrhythmia such as Torsades de pointes.Current single ion channel(hERG)-based assay generates-30% false results.The aim is to establish an advanced in vitro cardiotoxicity assay by incorporating high throughput multiple cardiac ion channel screening and human cardiomyocytes-based validation.METHODS Effects of drugs were tested on multiple cell lines expressing hERG,Nav1.5 and Cav1.2 by automated patch clamping.Subsequently,the results were validated with human pluripotent stem cell(hPSC)-derived cardiomyocytes(hPSC-CMs)in which ion currents and action potentials were measured by manual patch clamping.RESULTS We have tested the cardiotoxicity of monomers extracted from various medical herbs.Mitragynine is the major bioactive compound isolated from kratom,a therapeutic herb from the rain forest of South East Asia.As a popular stimulant,it has been associated with a number of acute fatal incidences.We observed a typical torsadogenic hazard of mitragynine.It exerted a strong hERG inhibition in hERG-HEK293 cell line(IC50:5.2 μmol·L-1)and hPSC-CMs(IC50:0.91 μmol·L-1)without affecting other cardiac ion channels.Moreover,it caused a significant prolongation of action potential duration(APD)in hPSC-CMs(a-32.5%increase in APD at 50 and 90%repolarization).On the other hand,deoxylelephantopin,apotential anti-cancer reagent,demonstrated low cardiotoxicity.It exerted a week inhibition on hERG in HEK293 cells with an IC50 of 87.2 μmol·L-1,while the effective concentrations for suppressing the growth of cancer cells ranges from 2 to 20μmol·L-1.At 100μmol·L-1,deoxylelephantopin showed no effects on Cav1.2 and Nav1.5 and it failed to alter APD in hPSC-CMs.CONCLUSION We have successfully tested a newin vitro cardiotoxicity assay strategy which incorporates multiple cardiac ion channels screening and hPSC-CMs validation.This new strategy could facilitate the effective and efficient evaluation of existing and new drugs/reagents for potential pro-arrhythmic risk.

Process in the Research on Chemical Modification of Drugs with Low Herg Cardiac Toxicity

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects

The interactions between hERG potassium channel and blockers.

Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity

Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia

Reducing hERG Toxicity Using hERG Classification Model and Fragment-growing Network

Diverse Drug-Herg Potassium Channel Interactions

Reducing Herg Toxicity Using Reliable Herg Classification Model and Fragment Grow Model

Physicochemical Basis for Binding and Voltage‐Dependent Block of Herg Channels by Structurally Diverse Drugs

A Pharmacophore Modeling Study of Drugs Inducing Cardiotoxic Side Effects

Current Pharmacogenomic Studies on Herg Potassium Channels.

Novel Intramolecular Photoinduced Electron Transfer-Based Probe for the Human Ether-a-go-go-Related Gene (herg) Potassium Channel

In silico prediction of drug-hERG potassium channel interaction

Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel.

Exploring Chemical Substructures Essential for HERG K(+) Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues.

Mechanistic and Therapeutic Perspectives for Cardiac Arrhythmias: Beyond Ion Channels

Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors

Recent Developments in Computational Prediction of Herg Blockage

In Silico Prediction Of Herg Potassium Channel Blockage By Chemical Category Approaches

A Comprehensive Cardiotoxicity Assay by Combining High-Throughput Multiple Ion Channel Screening with Human Cardiomyocyte-Based Action Potential Validation